DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Manufacturer of Controlled Substances; Notice of Application
Pursuant to § 1301.33(a), Title 21 of the Code of Federal Regulations (CFR), this is notice that on June 28, 2011, Cerilliant Corporation, 811 Paloma Drive, Suite A, Round Rock, Texas 78665–2402, made application by renewal to the Drug Enforcement Administration (DEA) to be registered as a bulk manufacturer of the following basic classes of controlled substances:
Drug
Schedule
Cathinone (1235)
I
Methcathinone (1237)
I
N-Ethylamphetamine (1475)
I
N, N-Dimethylamphetamine (1480)
I
Aminorex (1585)
I
4-Methylaminorex (cis isomer) (1590)
I
Gamma-Hydroxybutyric acid (2010)
I
Methaqualone (2565)
I
1-Pentyl-3-(1-naphthoyl) indole (7118)
I
1-Butyl-3-(1-naphthoyl) indole (7173)
I
1-[2-(4-Morpholinyl) ethyl]-3-(1-naphthoyl) Indole (7200)
I
Alpha-ethyltryptamine (7249)
I
5-(1, 1-Dimethylheptyl)-2-[{1R, 3S)-3-hydroxycyclohexyl]-phenol (7297)
I
5-(1, 1-Dimethyloctyl)-2-[{1R, 3S)-3-hydroxycyclohexyl]-phenol (7298)
Lysergic acid diethylamide (7315)
I
2, 5-Dimethoxy-4-(n)-propylthiophenethylamine (7348)
I
Marihuana (7360)
I
Tetrahydrocannabinols (7370)
I
Mescaline (7381)
I
3, 4, 5-Trimethoxyamphetamine (7390)
I
4-Bromo-2, 5-dimethoxyamphetamine (7391)
I
4-Bromo-2, 5-dimethoxyphenethylamine (7392)
I
4-Methyl-2, 5-dimethoxyamphetamine (7395)
I
2, 5-Dimethoxyamphetamine (7396)
I
2, 5-Dimethoxy-4-ethylamphetamine (7399)
I
3, 4-Methylenedioxyamphetamine (7400)
I
5-Methoxy-3, 4-methylenedioxyamphetamine (7401)
I
N-Hydroxy-3, 4-methylendioxyamphetamine (7402)
I
3, 4-Methylendioxy-N-ethylamphetamine (7404)
I
3, 4-Methylenedioxymethamphetamine (7405)
I
4-Methoxyamphetamine (7411)
I
5-Methoxy-N-N-dimethyltryptamine (7431)
I
Alpha-methyltryptamine (7432)
I
Bufotenine (7433)
I
Diethyltryptamine (7434)
I
Dimethyltryptamine (7435)
I
Psilocybin (7437)
I
Psilocyn (7438)
I
5-Methoxy-N, N-diisopropyltyptamine (7439)
I
N-Benzylpiperazine (7493)
I
Acetyldihydrocodeine (9051)
I
Benzylmorphine (9052)
I
Codeine-N-oxide (9053)
I
Dihydromorphine (9145)
I
Heroin (9200)
I
Hydromorphinol (9301)
I
Methyldihydromorphine (9304)
I
Morphine-N-oxide (9307)
I
Normorphine (9313)
I
Pholcodine (9314)
I
Acetylmethadol (9601)
I
Allylprodine (9602)
I
Alphacetylmethadol except levo-alphacetylmethadol (9603)
I
Alphameprodine (9604)
I
Alphamethadol (9605)
I
Betacetylmethadol (9607)
I
Betameprodine (9608)
I
Betamethadol (9609)
I
Betaprodine (9611)
I
Hydroxypethidine (9627)
I
Noracymethadol (9633)
I
Norlevorphanol (9634)
I
Normethadone (9635)
I
Trimeperidine (9646)
I
Phenomorphan (9647)
I
1-Methyl-4-phenyl-4-propionoxypiperidine (9661)
I
Tilidine (9750)
I
Para-Fluorofentanyl (9812)
I
3-Methylfentanyl (9813)
I
Alpha-Methylfentanyl (9814)
I
Acetyl-alpha-methylfentanyl (9815)
I
Beta-hydroxyfentanyl (9830)
I
Beta-hydroxy-3-methylfentanyl (9831)
I
Alpha-Methylthiofentanyl (9832)
I
3-Methylthiofentanyl (9833)
I
Thiofentanyl (9835)
I
Amphetamine (1100)
II
Methamphetamine (1105)
II
Lisdexamfetamine (1205)
II
Phenmetrazine (1631)
II
Methylphenidate (1724)
II
Amobarbital (2125)
II
Pentobarbital (2270)
II
Secobarbital (2315)
II
Glutethimide (2550)
II
Nabilone (7379)
II
1-Phenylcyclohexylamine (7460)
II
Phencyclidine (7471)
II
1-Piperidinocyclohexanecarbonitrile (8603)
II
Alphaprodine (9010)
II
Cocaine (9041)
II
Codeine (9050)
II
Dihydrocodeine (9120)
II
Oxycodone (9143)
II
Hydromorphone (9150)
II
Diphenoxylate (9170)
II
Benzoylecgonine (9180)
II
Ethylmorphine (9190)
II
Hydrocodone (9193)
II
Levomethorphan (9210)
II
Levorphanol (9220)
II
Isomethadone (9226)
II
Meperidine (9230)
II
Meperidine intermediate-A (9232)
II
Meperidine intermediate-B (9233)
II
Meperidine intermediate-C (9234)
II
Methadone (9250)
II
Methadone intermediate (9254)
II
Dextropropoxyphene, bulk (non-dosage forms) (9273)
II
Morphine (9300)
II
Thebaine (9333)
II
Levo-alphacetylmethadol (9648)
II
Oxymorphone (9652)
II
Noroxymorphone (9668)
II
Racemethorphan (9732)
II
Alfentanil (9737)
II
Sufentanil (9740)
II
Tapentadol (9780)
II
Fentanyl (9801)
II
The company plans to manufacture small quantities of the listed controlled substances to make reference standards which will be distributed to their customers.
Any other such applicant, and any person who is presently registered with DEA to manufacture such substances, may file comments or objections to the issuance of the proposed registration pursuant to 21 CFR 1301.33(a).
Any such written comments or objections should be addressed, in quintuplicate, to the Drug Enforcement Administration, Office of Diversion Control, Federal Register Representative (ODL), 8701 Morrissette Drive, Springfield, Virginia 22152; and must be filed no later than March 19, 2012.
Dated: January 5, 2012.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration.